ENDRA Life Sciences (NDRA) FDA Approvals $5.31 +0.13 (+2.51%) Closing price 06/23/2026 04:00 PM EasternExtended Trading$5.38 +0.08 (+1.41%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ENDRA Life Sciences' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by ENDRA Life Sciences (NDRA). Over the past two years, ENDRA Life Sciences has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as TAEUS. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. TAEUS FDA Regulatory Events TAEUS is a drug developed by ENDRA Life Sciences for the following indication: Device. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Results - December 4,2025Results Drug: TAEUSAnnounced Date: December 4, 2025Indication: DeviceAnnouncementENDRA Life Sciences Inc announced new results from its 2025 TAEUS Liver device feasibility study demonstrating that TAEUS' thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI-PDFF gold standard at critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%.AI SummaryENDRA Life Sciences reported 2025 feasibility study results showing its TAEUS device’s thermo-acoustic fat fraction (TAFF) measurement closely matches MRI-PDFF at key liver fat fraction (LFF) decision points. In 40 subjects (BMI 21–47), TAEUS performed strongly at the 12–17% range (grade 1–2 steatosis) with average PPV 100%, NPV 94% and accuracy 95%. At the 20–22% range (grade 2–3 steatosis) it showed average PPV 90%, NPV 94% and accuracy 94%. These thresholds are used to decide treatment, reimbursement, and trial inclusion. High PPV means TAEUS can reliably identify patients above treatment cutoffs; high NPV helps rule out those below them. Because TAEUS is designed as a low‑cost, point‑of‑care option (targeted cost under $200), these results support its potential to reduce reliance on expensive MRI‑PDFF exams and enable more frequent, practical monitoring during drug development and clinical care.Read AnnouncementResults - December 4,2025Results Drug: TAEUSAnnounced Date: December 4, 2025Indication: DeviceAnnouncementENDRA Life Sciences Inc announced new results from its 2025 TAEUS Liver device feasibility study demonstrating that TAEUS' thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI-PDFF gold standard at critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%.AI SummaryENDRA Life Sciences reported 2025 feasibility results showing its TAEUS device’s thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI‑PDFF gold standard at key liver fat fraction (LFF) thresholds used for clinical decisions. In a 40‑subject study (BMI 21–47), TAEUS matched MRI‑PDFF performance in the critical 12–17% and 20–22% LFF ranges that separate mild, moderate and severe steatosis. Performance at those cutoffs was strong: for 12–17% LFF, average PPV was 100%, NPV 94%, and accuracy 95%; for 20–22% LFF, average PPV was 90%, NPV 94%, and accuracy 94%. High PPV supports identifying patients above treatment or trial thresholds, while high NPV helps rule out those below. ENDRA positions TAEUS as a lower‑cost, point‑of‑care alternative to MRI‑PDFF for patient stratification and frequent trial monitoring, potentially reducing screening and monitoring costs and enabling more accessible longitudinal liver fat measurement.Read AnnouncementPreliminary Results - November 20,2025Preliminary Results Drug: TAEUSAnnounced Date: November 20, 2025Indication: DeviceAnnouncementENDRA Life Sciences Inc. announces encouraging preliminary results from a single-site clinical feasibility study evaluating its improved TAEUS Liver device for quantifying liver fat fraction, which is a key biomarker of steatotic liver disease ("SLD").Read Announcement ENDRA Life Sciences FDA Events - Frequently Asked Questions Has ENDRA Life Sciences received FDA approval? As of now, ENDRA Life Sciences (NDRA) has not received any FDA approvals for its therapy in the last two years. What drugs has ENDRA Life Sciences submitted to the FDA? In the past two years, ENDRA Life Sciences (NDRA) has reported FDA regulatory activity for TAEUS. What is the most recent FDA event for ENDRA Life Sciences? The most recent FDA-related event for ENDRA Life Sciences occurred on December 4, 2025, involving TAEUS. The update was categorized as "Results," with the company reporting: "ENDRA Life Sciences Inc announced new results from its 2025 TAEUS Liver device feasibility study demonstrating that TAEUS' thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI-PDFF gold standard at critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%." What conditions do ENDRA Life Sciences' current drugs treat? Currently, ENDRA Life Sciences has one therapy (TAEUS) targeting the following condition: Device. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events AgomAb Therapeutics FDA EventsAmylyx Pharmaceuticals FDA EventsCoherus Oncology FDA EventsDiaMedica Therapeutics FDA EventsEntera Bio FDA EventsGalectin Therapeutics FDA EventsGilead Sciences FDA EventsJaguar Animal Health FDA EventsKalaris Therapeutics FDA EventsMicrobot Medical FDA EventsPhathom Pharmaceuticals FDA EventsQuoin Pharmaceuticals FDA EventsSilexion Therapeutics FDA EventsAbbVie FDA EventsTeleflex FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies Vyome FDA Events Co-Diagnostics FDA Events SeaStar Medical FDA Events Sintx Technologies FDA Events Quoin Pharmaceuticals FDA Events Intelligent Bio Solutions FDA Events Bluejay Diagnostics FDA Events Beyond Air FDA Events PAVmed FDA Events Aethlon Medical FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare and Medical Stocks FDA progress for NASDAQ:NDRA last updated on 12/5/2025 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersMy feud with Zohran MamdaniNearly 40% of Americans now hold a positive view of socialism - and former hedge fund manager Whitney Tilson s...Stansberry Research | SponsoredQuick favor to ask youBill Poulos is giving away his 'Safe Trade Options Formula' book at no charge - the same book that sells for $...Profits Run | SponsoredTrump Takes Emergency Action - Plus Elon Musk's New VentureElon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...Altimetry | SponsoredTop Banks Warn: A Strange Day is Coming to AmericaGoldman Sachs and Morgan Stanley are warning clients about a developing crisis that could suppress portfolio g...TradeSmith | SponsoredA drilling crew just broke a record nobody expectedA drilling crew in Beaver County, Utah hit 15,765 feet of solid granite in 16 days - a job the Department of E...Behind the Markets | SponsoredKarp just filed Form 144On May 12, 2026, Palantir CEO Alex Karp filed to sell 585,000 shares - roughly $95.93 million. Combined with f...Porter & Company | SponsoredPH: Do THESE 4 things to your bank account now …In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...Weiss Ratings | SponsoredIt's time to "buy the dip" in goldGold just posted a significant correction - and one analyst calls it the biggest buy-the-dip opportunity of th...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ENDRA Life Sciences Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ENDRA Life Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Results - December 4,2025Results Drug: TAEUSAnnounced Date: December 4, 2025Indication: DeviceAnnouncementENDRA Life Sciences Inc announced new results from its 2025 TAEUS Liver device feasibility study demonstrating that TAEUS' thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI-PDFF gold standard at critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%.AI SummaryENDRA Life Sciences reported 2025 feasibility study results showing its TAEUS device’s thermo-acoustic fat fraction (TAFF) measurement closely matches MRI-PDFF at key liver fat fraction (LFF) decision points. In 40 subjects (BMI 21–47), TAEUS performed strongly at the 12–17% range (grade 1–2 steatosis) with average PPV 100%, NPV 94% and accuracy 95%. At the 20–22% range (grade 2–3 steatosis) it showed average PPV 90%, NPV 94% and accuracy 94%. These thresholds are used to decide treatment, reimbursement, and trial inclusion. High PPV means TAEUS can reliably identify patients above treatment cutoffs; high NPV helps rule out those below them. Because TAEUS is designed as a low‑cost, point‑of‑care option (targeted cost under $200), these results support its potential to reduce reliance on expensive MRI‑PDFF exams and enable more frequent, practical monitoring during drug development and clinical care.Read Announcement
Results - December 4,2025Results Drug: TAEUSAnnounced Date: December 4, 2025Indication: DeviceAnnouncementENDRA Life Sciences Inc announced new results from its 2025 TAEUS Liver device feasibility study demonstrating that TAEUS' thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI-PDFF gold standard at critical liver fat fraction (LFF) thresholds of 12-17% and 20-22%.AI SummaryENDRA Life Sciences reported 2025 feasibility results showing its TAEUS device’s thermo-acoustic fat fraction (TAFF) measurement closely tracks the MRI‑PDFF gold standard at key liver fat fraction (LFF) thresholds used for clinical decisions. In a 40‑subject study (BMI 21–47), TAEUS matched MRI‑PDFF performance in the critical 12–17% and 20–22% LFF ranges that separate mild, moderate and severe steatosis. Performance at those cutoffs was strong: for 12–17% LFF, average PPV was 100%, NPV 94%, and accuracy 95%; for 20–22% LFF, average PPV was 90%, NPV 94%, and accuracy 94%. High PPV supports identifying patients above treatment or trial thresholds, while high NPV helps rule out those below. ENDRA positions TAEUS as a lower‑cost, point‑of‑care alternative to MRI‑PDFF for patient stratification and frequent trial monitoring, potentially reducing screening and monitoring costs and enabling more accessible longitudinal liver fat measurement.Read Announcement
Preliminary Results - November 20,2025Preliminary Results Drug: TAEUSAnnounced Date: November 20, 2025Indication: DeviceAnnouncementENDRA Life Sciences Inc. announces encouraging preliminary results from a single-site clinical feasibility study evaluating its improved TAEUS Liver device for quantifying liver fat fraction, which is a key biomarker of steatotic liver disease ("SLD").Read Announcement
